Atossa Genetics Opens Enrollment in Phase 2 Study of Oral

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
70
Atossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer

SEATTLE, July 13, 2018 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has opened a Phase 2 study of its proprietary oral Endoxifen to treat breast cancer in the “window of opportunity” setting, which is the period between diagnosis of breast cancer and surgery.

“Once a patient is diagnosed with breast cancer, there is a window of time, typically a number of weeks, before definitive surgery is performed,” commented Steve Quay, Ph.D., MD, President and CEO of Atossa. “Our goal with this study is to show that our proprietary oral Endoxifen can modify the cancer activity in estrogen-receptor-positive patients during this ‘window of opportunity.' Tamoxifen, the current standard of care, has not been effective in this setting, probably because it can take 50-200 days to reach steady-state of Endoxifen blood levels, while the surgery is usually completed within 30 to 45 days of diagnosis. Because our Phase 1 study indicated that our oral Endoxifen reaches therapeutic levels within 8 hours and therapeutic steady-state levels in only seven days, we are optimistic we can achieve a valuable treatment effect,” added Dr. Quay. 

The Pilot Phase of the study will initially enroll up to eight newly-diagnosed patients with Estrogen Receptor Positive (ER+) and HER2 negative (HER2-) stage 1 or 2 invasive breast cancer, requiring mastectomy or lumpectomy. Patients will receive Atossa’s proprietary oral Endoxifen for at least 21 days from the time of diagnosis up to the day of surgery. Provided tumor activity reduction is demonstrated in at least two patients, an additional 17 patients will be enrolled for a total of 25. The U.S. FDA has provided a guidance document on “window of opportunity” or neoadjuvant studies entitled “Guidance for Industry Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval.” URL: https://www.fda.gov/downloads/drugs/guidances/ucm305501.pdf . The Company is using this document to inform this study and its design.

The primary endpoint is to determine if the administration of oral Endoxifen reduces the tumor activity as measured by Ki-67, which is a marker of cellular proliferation. The secondary endpoints are safety and tolerability and assessment of the study drug on expression levels of both estrogen and progesterone receptors. The impact on additional markers of cellular activity will also be explored.

The Phase 2 study is being conducted on behalf of Atossa by CPR Pharma Services Pty Ltd., Thebarton, SA, Australia. CPR Pharma recently completed the successful Phase 1 study of Atossa’s oral and topical Endoxifen in women.

A summary of Atossa’s current Endoxifen clinical pipe-line is as follows:

  • Phase 2 study of oral Endoxifen to treat stage 1 or 2 breast cancer that is ER+ and HER2- in the “window of opportunity” setting: now open  
  • Phase 2 study of topical Endoxifen to treat mammographic breast density: opened in June 2018  
  • Phase 1 study of topical Endoxifen to treat gynecomastia in men: dosing and clinical visits completed; preliminary data to be reported in Q3 2018  
  • Phase 2 study of topical Endoxifen to treat gynecomastia in men: subject to Phase 1 results, the Phase 2 is anticipated to commence in Q4 2018  
  • Phase 2 study of oral Endoxifen to treat breast cancer survivors who are refractory to tamoxifen: anticipated to commence in 2H 2018

Atossa’s Proprietary Endoxifen

Endoxifen is an active metabolite of tamoxifen. Tamoxifen is an FDA-approved drug to prevent new breast cancer as well as recurrent breast cancer in breast cancer patients. Tamoxifen itself must be broken down by the liver into active compounds (metabolites), of which Endoxifen is the most active. Up to half of the patients taking tamoxifen, however, do not produce therapeutic levels of Endoxifen, frequently because of metabolism problems. Tamoxifen also has some very rare but serious adverse side effects, which can include stroke, blood clots, pulmonary embolism, blindness, and endometrial cancer. Because of these drawbacks of Tamoxifen, Atossa is developing oral and topical forms of Endoxifen.

Atossa has completed a comprehensive Phase 1 clinical study using both its topical and an oral formulation of Endoxifen. Results from the Phase 1 study indicated that there were no clinically significant safety signals and no clinically significant adverse events and both the oral and topical Endoxifen were well tolerated. In the topical arm of the study, low but measurable Endoxifen levels were detected in the blood in a dose-dependent fashion. In the oral arm of the study, participants exhibited dose-dependent Endoxifen levels that met or exceeded the published therapeutic level. The median time for patients in the study to reach the steady-state serum levels of Endoxifen while taking daily doses of Atossa’s oral Endoxifen was 7 days. Published literature indicates that it takes approximately 50-200 days for patients to reach steady-state Endoxifen levels when taking daily doses of oral tamoxifen.

Oral Endoxifen Opportunities

In addition to the window of opportunity setting, Atossa is also developing our proprietary oral Endoxifen for breast cancer patients who are refractory to Tamoxifen. Approximately one million breast cancer patients take Tamoxifen to prevent recurrent and new breast cancer; however, up to 50% of those patients are refractory to Tamoxifen, meaning they do not produce therapeutic levels of Endoxifen. This is often because the Tamoxifen is not properly metabolized into Endoxifen. “We believe our oral Endoxifen may provide an effective treatment supplement or option for these refractory patients because Endoxifen, unlike Tamoxifen, does not require liver metabolism,” stated Steve Quay.

Topical Endoxifen Opportunities

Atossa is developing its proprietary topical Endoxifen to reduce MBD, which has been shown in studies conducted by others to be an independent risk factor for developing breast cancer. To date, 34 U.S. states have enacted laws requiring that findings of MBD be communicated to the patient. According to the National Cancer Institute approximately 10 million women in the U.S. have high breast density (BI-RAD level C or D with “D” being the highest). Although oral Tamoxifen has been shown to reduce MBD, the benefit-risk ratio is generally not acceptable to most patients. For example, it is estimated that only ~ 2% of women at high-risk of developing breast cancer, including those with MBD, take oral Tamoxifen to prevent breast cancer because of the risks of, or actual side-effects of oral Tamoxifen. There is no FDA-approved treatment for MBD.

In June 2018, Atossa opened a Phase 2 double-blinded placebo-controlled study of topical Endoxifen to treat MBD. The study is being conducted at Stockholm South General Hospital in Sweden by principal investigator Dr. Per Hall, MD, Ph.D., Head of the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet. The primary endpoint is MBD reduction, as well as safety and tolerability. The study includes 90 participants: 30 on each of two different doses of topical Endoxifen and 30 on placebo.

Atossa is also developing topical Endoxifen for a condition in men called gynecomastia, which is male breast enlargement, and according to the Mayo Clinic affects 25% of men in the U.S. between the ages of 50-69, or approximately 10 million men. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone is low compared to estrogen. In prostate cancer treatment, testosterone is suppressed with androgen deprivation therapy resulting is higher estrogen levels that usually triggers gynecomastia. One recent study indicates that up to 90% of men taking androgen deprivation therapy suffer from gynecomastia and breast pain (Handoo Rhee, et al., October 18, 2014,  BJU International ). There is no FDA-approved pharmaceutical to treat gynecomastia. Current therapeutic approaches in these patients include the daily use of oral estrogen-suppressing medications and prophylactic breast bud irradiation which is often repeated.

Atossa has completed dosing and clinical visits in a Phase 1 study in men using topical Endoxifen and it plans to announce preliminary results from this study in the third quarter 2018. The objectives of the placebo-controlled, repeat dose study of 24 healthy male volunteers are to assess the pharmacokinetics of a proprietary topical Endoxifen dosage form over 28 days, as well as to assess safety and tolerability. 

About Atossa Genetics

Atossa Genetics Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa's products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others with respect to fulvestrant, such as patent rights, potential market sizes for Atossa’s drugs under development and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Genetics Company Contact:

Atossa Genetics Inc. Kyle Guse CFO and General Counsel (O) 866 893-4927 kyle.guse@atossagenetics.com

Investor Relations Contact:

Scott Gordon CoreIR 377 Oak Street Concourse 2 Garden City, NY 11530 Office: 516 222-2560 scottg@CoreIR.com

Source: Atossa Genetics Inc.

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 343

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 34

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 306

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 0

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 635

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 119

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading

Top 5 Most Recently Viewed Articles

Cordance Medical Secures $8M Seed Funding for Brain Solutions

Updated Category News Views 235

Groundbreaking Seed Financing for Cordance Medical Cordance Medical, a leader in noninvasive focused ultrasound technology for treating brain diseases, has successfully completed an oversubscribed seed financing round. This milestone was highlighted by exceeding the initial $8 million target, with participation from both new and existing investors such as Shanda Grab...

Continue Reading
Man Group PLC Discloses Open Positions for Aviva PLC

Updated Category News Views 179

Man Group PLC Reports on Relevant Securities In a significant disclosure, Man Group PLC has announced its public opening position in relation to Aviva PLC, emphasizing transparency in its dealings concerning relevant securities. The regulations governing such disclosures necessitate comprehensive reporting, particularly when interests exceed 1% of the relevant securities....

Continue Reading
Baird Raises Griffon Corp Price Target to $92, Outperform Rating

Updated Category News Views 63

Baird Updates Griffon Corp's Stock Projection Baird has elevated its price target on shares of Griffon Corp (NYSE: GFF) from $84.00 to $92.00. This revision to the target price comes with a maintained Outperform rating, signaling strong confidence in the company's outlook. The analyst from Baird forecasts a gradual increase in Griffon's fiscal fourth-quarter financial...

Continue Reading
Experience SoCal Car Culture at SPARQ's LA Auto Show Exhibit

Updated Category News Views 316

SPARQ Returns to LA Auto Show with Exciting Exhibit California's automotive AI startup SPARQ is making waves by returning to the highly anticipated Los Angeles Auto Show this November. This year, visitors can expect an immersive experience inside the Concourse Hall, showcasing an impressive lineup of hypercars, Formula 1 vehicles, and famous cars from iconic films such as...

Continue Reading
Sagent Behavioral Health: A New Era for Mental Wellness Providers

Updated Category News Views 616

Sagent Behavioral Health: Transforming Behavioral Healthcare Sagent Behavioral Health marks a significant advancement in the provision of mental health services in the Midwest. With the consolidation of Nystrom & Associates and its affiliated brands, including Ellie Mental Health, LifeWorks, and several others, this new entity aims to create a unified and robust network...

Continue Reading